DANIA BEACH, Fla.–(BUSINESS WIRE)–IntelePeer, the trusted leader in AI-powered automation and analytics for customer and patient interactions, today introduced at HLTH 2025 the SmartAnalytics™ Starter Pack. The Pack gives multi-site healthcare organi…
Category: News
Yunqi Capital Issues Letter to STAAR Surgical’s Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction
HONG KONG–(BUSINESS WIRE)–Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today iss…
Science Corp.’s PRIMA BCI Implant Restores Functional Central Vision to Patients with Geographic Atrophy Caused By Age-Related Macular Degeneration, a Leading Cause of Blindness, The New England Journal of Medicine Reports
ALAMEDA, Calif.–(BUSINESS WIRE)–The New England Journal of Medicine (NEJM) today published a peer-reviewed original paper with the results of a landmark clinical trial demonstrating the efficacy of Science Corporation’s PRIMA brain-computer interface…
US FDA Approves Glaukos’ New Eye Therapy
The U.S. Food and Drug Administration has approved a new eye therapy from Glaukos Corp, giving patients a less painful option to treat a progressive condition that can… Reuters Health Information
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)– #AAO2025–Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12 month results from the company’s Phase …
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 an…
Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
BOSTON–(BUSINESS WIRE)–Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
Adalimumab Outperforms Standard Therapy in Uveitis Study
Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy are less likely to rely on corticosteroids when they receive adalimumab instead of conventional agents. Medscape Medical News
Het programma van Dompé voor NAION geselecteerd voor het baanbrekende FDA Commissioner’s National Priority Voucher programma
MILAAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, een toonaangevend biofarmaceutisch bedrijf met activiteiten in Italië en de VS, heeft vandaag bekendgemaakt dat het door de Amerikaanse Food and Drug Administration (FDA) is geselecteerd om deel te ne…
Le programme de Dompé dans le domaine de la NAION sélectionné pour le programme national prioritaire du commissaire de la FDA
MILAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, une société biopharmaceutique de premier plan implantée en Italie et aux États-Unis, a annoncé aujourd’hui avoir été sélectionnée par la Food and Drug Administration (FDA) américaine pour participer au…
Seleccionan el programa de Dompé en NAION para el emblemático programa Acerca del programa piloto de Vales de Prioridad Nacional del Comisionado de la FDA
MILAN Y SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, una biofarmacéutica líder con operaciones en Italia y Estados Unidos, ha anunciado hoy que ha sido seleccionada por la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) para participar…
Dompés Programm zu NAION wird für richtungsweisendes FDA-Programm Commissioner’s National Priority Voucher ausgewählt
MAILAND & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, ein führendes biopharmazeutisches Unternehmen mit Niederlassungen in Italien und den USA, gab heute bekannt, dass es von der US-amerikanischen Food and Drug Administration (FDA) für die Teilnahme am …
Il programma di Dompé sulla NOIA-NA selezionato per il prestigioso programma Commissioner’s National Priority Voucher della FDA
MILANO & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, un’azienda biofarmaceutica leader con sedi operative in Italia e negli Stati Uniti, oggi ha annunciato di essere stata selezionata dalla Food and Drug Administration (FDA) statunitense per partecipare…
Conference MDAngle: AAO 2025 Non-AMD Retinal Disorders
Insights from AAO 2025, including anticipated presentations, key takeaways, and how emerging research on non-AMD retinal disorders may affect patient care. Medscape
AAO 2025: Previewing Key Discussions in Retinal Disorders
Dr Sunir Garg looks ahead to presentations on new developments in retinal eye disease treatments, medication risks, and updated screening guidelines. Medscape
Pickleball Peril? Eye Injuries Surge in Adults Over 50
Thousands of patients have presented to emergency departments with ocular injuries sustained while playing the increasingly popular sport, researchers estimate. Medscape Medical News
Samsara Vision Expands U.S. and Puerto Rico Clinical Study Sites for the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®)
FAR HILLS, N.J.–(BUSINESS WIRE)– #AMD–Samsara Vision Expands U.S. and Puerto Rico Clinical Study Sites for the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®)
IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes
CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina and other therapeutic areas. As part of this expansi…
Y.ora Vision Launches Following Licensing Agreement Between SERI and Eyexora Global to Advance Minimally Invasive Glaucoma Surgery
SINGAPORE–(BUSINESS WIRE)– #glaucoma–Y.ora Vision Launches Following Licensing Agreement Between SERI and Eyexora Global to Advance Minimally Invasive Glaucoma Surgery
Heru Surpasses 1 Million Eyes Tested, Cementing Leadership in AI-Powered Vision Diagnostics
MIAMI–(BUSINESS WIRE)– #automation–Heru, the leader in AI-powered vision diagnostics, today announced it has surpassed a landmark achievement of one million eyes tested on its wearable platform. This significant milestone underscores the company’s a…